NDAInjectionInjectablePriority Review
Approved
Aug 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
PHOTOFRIN (porfimer sodium) by Lavipharm is 12. First approved in 2003.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOTOFRIN (porfimer sodium) is a photosensitizing agent used in photodynamic therapy (PDT) for lung cancer treatment. It works through a two-stage process: IV administration followed by illumination with 630 nm laser light, which generates reactive oxygen species and causes tumor cell death through both radical reactions and vascular occlusion. The drug exhibits selective tumor retention combined with selective light delivery for targeted cytotoxicity.
LOE Approaching
With LOE approaching, the brand team will likely shift focus toward lifecycle extension strategies, post-LOE planning, and potential cost reduction initiatives rather than growth-stage expansion.
Mechanism of Action
12.1 Mechanism of Action The cytotoxic and antitumor actions of PHOTOFRIN are light and oxygen dependent. Photodynamic therapy (PDT) with PHOTOFRIN is a two-stage process. The first stage is the intravenous administration of PHOTOFRIN. Clearance from a variety of tissues occurs over 40-72 hours,…
Worked on PHOTOFRIN at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.